16 October 2023 - If approved, dostarlimab would become the first new frontline treatment option in the European Union in decades and the only immuno-oncology combination regimen available for this patient population with high unmet need.

GSK today announced the CHMP of the EMA has adopted a positive opinion recommending approval of Jemperli (dostarlimab) in combination with carboplatin-paclitaxel (chemotherapy), for the treatment of adult patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.

Read GSK press release